LogicBio Therapeutics Inc

NASDAQ:LOGC  
6.96
-0.14 (-1.97%)
Earnings Announcements

LogicBio Therapeutics Reports Third Quarter 2020 Financial Results And Provides Business Update

Published: 11/09/2020 12:01 GMT
LogicBio Therapeutics Inc (LOGC) - Logicbio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update.
Q3 Loss per Share $0.34.
Q3 Earnings per Share Estimate $-0.41 -- Refinitiv Ibes Data (analyst estimates).
Logicbio Therapeutics - Cash, Equivalents at Quarter End, Follow-on Offering Proceeds, Will Be Sufficient to Fund Expenses, Capex for at Least 12 Months.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.33

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.